Article in Pharmaceutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
13 authors.
Daniel OliveiraDepartment of Pharmacotherapy and Experimental Therapeutics, University of North Carolina Chapel Hill, 120 Mason Farm Road, Genetic Medicine Building 7361, Chapel Hill, NC 27599, USA.
Daniela CruzRTI International, 3040 E Cornwallis Rd., Research Triangle Park, NC 27709, USA.ORCID 0000-0001-5701-1868
Leanna P K LevinRTI International, 3040 E Cornwallis Rd., Research Triangle Park, NC 27709, USA.
Linying LiRTI International, 3040 E Cornwallis Rd., Research Triangle Park, NC 27709, USA.
Chasity A NortonRTI International, 3040 E Cornwallis Rd., Research Triangle Park, NC 27709, USA.ORCID 0000-0001-6730-5181
Georgina DobekDepartment of Comparative Medicine, Tulane University School of Medicine, 1430 Tulane Avenue, New Orleans, LA 70112, USA.
Xiaolei WangDepartment of Comparative Medicine, Tulane University School of Medicine, 1430 Tulane Avenue, New Orleans, LA 70112, USA.ORCID 0000-0003-4081-8985
Ronald VeazeyDepartment of Comparative Medicine, Tulane University School of Medicine, 1430 Tulane Avenue, New Orleans, LA 70112, USA.ORCID 0000-0002-6298-2391
Meagan WatkinsTulane National Biomedical Research Center, Division of Comparative Pathology, 18703 Three Rivers Road, Covington, LA 70433, USA.
Amanda P SchauerDepartment of Pharmacotherapy and Experimental Therapeutics, University of North Carolina Chapel Hill, 120 Mason Farm Road, Genetic Medicine Building 7361, Chapel Hill, NC 27599, USA.ORCID 0000-0002-7026-7224
Julie B DumondDepartment of Pharmacotherapy and Experimental Therapeutics, University of North Carolina Chapel Hill, 120 Mason Farm Road, Genetic Medicine Building 7361, Chapel Hill, NC 27599, USA.ORCID 0000-0002-3500-5819
Leah M JohnsonRTI International, 3040 E Cornwallis Rd., Research Triangle Park, NC 27709, USA.
Mackenzie L CottrellDepartment of Pharmacotherapy and Experimental Therapeutics, University of North Carolina Chapel Hill, 120 Mason Farm Road, Genetic Medicine Building 7361, Chapel Hill, NC 27599, USA.ORCID 0000-0002-0291-5111
Funding
Tulane NPRC SPF Sheltered Outdoor Enclosure ExpansionP51OD011104 · OD · TULANE UNIVERSITY OF LOUISIANA · PI L Lee HAMM · 2012 to 2026
$142.4M
Virology, Immunology, and Microbiology CoreP30AI050410 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2001 to 2026
$76.9M
Eunice Kennedy Shriver National Institute of Child Health and Human Development R61AI149499/R33AI149499National Institute of Allergy and Infectious Diseases R61AI149499/R33AI149499NIAID NIH HHS P30 AI050410NIH HHS P51 OD011104
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Harnessing Pharmacokinetic Modeling to Develop a Long-Acting Subcutaneous HIV Treatment Platform for Young Children. · full record | OpenQuestion